Efficacy of Intralesional Bevacizumab Versus Intralesional Triamcinolone Acetonide Injection in the Treatment of Keloids: A Randomized Clinical Trial
International Journal of Dermatology · 2026
DOI: 10.1111/ijd.70548 ↗At a glance
Randomisierte kontrollierte Studie in International Journal of Dermatology, 2026. Written by Rana F Hilal and 5 co-authors. Institution: Department of Dermatology, Kasr Al Ainy Teaching Hospital, Cairo University, Cairo, Egypt. Major MEDLINE topics: Triamcinolone Acetonide, Bevacizumab, Keloid, Angiogenesis Inhibitors. 24 references.
Abstract (original language)
Background
Keloids are an abnormal fibroproliferative disorder that often causes pruritus, pain, and hyperpigmentation, thereby significantly impacting quality of life. Vascular endothelial growth factor (VEGF) is upregulated in scars and, therefore, can be a potential target for their treatment.
Objectives
Our aim was to evaluate the efficacy and safety of intralesional triamcinolone acetonide (TAC) versus intralesional bevacizumab injection in the treatment of post‐traumatic keloids.
Methods
This randomized clinical trial was conducted on 28 adult patients with post‐traumatic keloids. Patients were randomized into two groups; one group received intralesional triamcinolone acetonide, and the other received intralesional bevacizumab. Injections were done monthly. Patients received a total of three sessions. Therapeutic efficacy was defined in terms of the modified Vancouver Scar Scale (mVSS), erythema index by spectrophotometry, histopathological evaluation, and biochemical assessment of VEGF, collagen type I, and collagen type III levels.
Results
A statistically significant difference in mVSS was observed between the triamcinolone acetonide and bevacizumab groups, favoring the TAC group. The TAC group showed a significant decrease in VEGF level and an increase in collagen type III after treatment. The bevacizumab group showed significant improvement in the spacing between collagen fibers after treatment. The patient satisfaction score and the physician global assessment revealed superior outcomes regarding intralesional triamcinolone acetonide.
Conclusion
Despite the superior results observed with triamcinolone, bevacizumab warrants further investigation to determine whether it can be used for early and vascular keloids or as an adjuvant to optimize results. Trial Registration: ClinicalTrials.gov identifier: NCT07014280. image
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Dermatology, Kasr Al Ainy Teaching Hospital, Cairo University, Cairo, Egypt.
- Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Cairo University, Cairo, Egypt.
ORCID profiles: Rana F Hilal, Amira Elbendary, Zeinab A Nour, Nanis Ragab
Cite
APA
Hilal, R. F., Osama, N., El-Tahlawi, S., Elbendary, A., Nour, Z. A., & Ragab, N. (2026). Efficacy of Intralesional Bevacizumab Versus Intralesional Triamcinolone Acetonide Injection in the Treatment of Keloids: A Randomized Clinical Trial. International Journal of Dermatology. https://doi.org/10.1111/ijd.70548
Vancouver
Hilal RF, Osama N, El-Tahlawi S, Elbendary A, Nour ZA, Ragab N. Efficacy of Intralesional Bevacizumab Versus Intralesional Triamcinolone Acetonide Injection in the Treatment of Keloids: A Randomized Clinical Trial. International Journal of Dermatology. 2026. doi:10.1111/ijd.70548
BibTeX
@article{Hilal2026,
author = {Hilal, Rana F and Osama, Nourhan and El-Tahlawi, Samar and Elbendary, Amira and Nour, Zeinab A and Ragab, Nanis},
title = {Efficacy of Intralesional Bevacizumab Versus Intralesional Triamcinolone Acetonide Injection in the Treatment of Keloids: A Randomized Clinical Trial},
journal = {International Journal of Dermatology},
year = {2026},
doi = {10.1111/ijd.70548}
}
EUVIMED